



RESPONSE TO EDITORIAL COMMENTS

The Swedish prostate cancer guidelines: response to Axcrone and Löffeler

We appreciate that Axcrone and Löffeler have read and commented not only on the summary of the Swedish Prostate Cancer Guidelines in this journal but also on the guidelines themselves and on the separate guidelines on organized prostate cancer testing (available in English at <https://cancercentrum.se/samverkan/vara-uppdrag/prevention-och-tidig-upptackt/prostatacancertestning/>).

We agree with Axcrone and Löffeler that few 85-year-old men with a localized Gleason score 8 prostate cancer would benefit from curative treatment. Our guidelines recommend that the management of patients with high-risk disease who have over 5 years' life expectancy should be discussed at a multidisciplinary team meeting. It was not our intention to give the impression that we recommend curative treatment for all these patients, but we understand that the text might have given this impression and are grateful to Axcrone and Löffeler for making us aware of this. We have now rephrased the guidelines to make it clear that curative treatment for

high-risk cancer (Cambridge Prognostic Group 4) should be considered mainly those patients who have a life expectancy over 10 years.

ORCID

Ola Bratt  <http://orcid.org/0000-0002-9198-9445>

Ola Bratt 

*Department of Urology, Institute of Clinical Sciences,
Sahlgrenska Academy, University of Göteborg, Göteborg,
Sweden*

 ola.bratt@gu.se

Received 11 July 2022; accepted 14 July 2022

© 2022 Acta Chirurgica Scandinavica Society